Conclusions: Prasinezumab therapy had no meaningful effect on global or imaging measures of Parkinson's disease progression as compared with placebo and was associated with infusion reactions. (Funded by F. Hoffmann-La Roche and Prothena Biosciences; PASADENA ClinicalTrials.gov number, NCT03100149.).
Prasinezumab therapy had no meaningful ef... - Cure Parkinson's
Prasinezumab therapy had no meaningful effect on global or imaging measures of Parkinson's disease progression
3 Replies
•
The first sentence of the abstract says "Aggregated α-synuclein plays an important role in the pathogenesis of Parkinson's disease." Maybe, just maybe, the entire premise is wrong...
As I cohort in that trial for the past 5 years I have to concur with this conclusion. I hung in there throughout that time as the early years of Parkinsons for many are as they say, the “honeymoon” years. Furthermore, I had no adverse effects from the medication . . . and the clinical trial proctors were very professional. Although I have not officially heard this trial has been canceled I certainly have no regrets in having been a part of such. Now looking for another trial that may help lead to a better treatment or cure for this affliction!
Here is some more detail: medpagetoday.com/neurology/...
